ACTINIUM PHARMACEUTICALS INC (ATNM) Stock Overview
USA - NYSEARCA:ATNM - US00507W2061 - Common Stock
ATNM Key Statistics, Chart & Performance
The current stock price of ATNM is 1.46 USD. In the past month the price decreased by -8.18%. In the past year, price decreased by -19.78%.
ATNM Latest News, Press Relases and Analysis
ATNM Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 21.68 | 405.55B | ||
| AMGN | AMGEN INC | 13.7 | 160.87B | ||
| GILD | GILEAD SCIENCES INC | 15.87 | 152.38B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.61 | 106.87B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 63.14B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.67 | 61.27B | ||
| ARGX | ARGENX SE - ADR | 91.6 | 51.94B | ||
| INSM | INSMED INC | N/A | 35.04B | ||
| ONC | BEONE MEDICINES LTD-ADR | 5.11 | 34.76B | ||
| BNTX | BIONTECH SE-ADR | N/A | 25.28B | ||
| NTRA | NATERA INC | N/A | 24.94B | ||
| BIIB | BIOGEN INC | 8.93 | 20.97B |
Related stock screener links
About ATNM
Company Profile
Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel targeted therapies. The company is headquartered in New York City, New York and currently employs 37 full-time employees. The company went IPO on 2014-03-26. The firm is advancing its lead product candidate Actimab-A, a CD33 targeting therapeutic, as potential backbone therapy in acute myeloid leukemia (AML) and other myeloid malignancies leveraging the mutation agnostic alpha-emitter radioisotope payload Actinium-225 (Ac-225). The firm is engaged with the National Cancer Institute (NCI) under the Cooperative Research and Development Agreement (CRADA) for development of Actimab-A in AML and other myeloid malignancies. ATNM-400 is the Company's novel non-PSMA targeting Ac-225 radiotherapy for prostate cancer. Iomab-ACT, its conditioning candidate, is being developed to improve patient access and outcomes for potentially curative cell and gene therapies. Its Iomab-B program is an induction and conditioning agent prior to bone marrow transplant in patients with r/r AML, which it is seeking a potential strategic partner for the United States.
Company Info
ACTINIUM PHARMACEUTICALS INC
100 Park Ave., 23Rd Floor
New York City NEW YORK 10016 US
CEO: Sandesh Seth
Employees: 37
Phone: 16466773870
ACTINIUM PHARMACEUTICALS INC / ATNM FAQ
What is the stock price of ACTINIUM PHARMACEUTICALS INC today?
The current stock price of ATNM is 1.46 USD.
What is the ticker symbol for ACTINIUM PHARMACEUTICALS INC stock?
The exchange symbol of ACTINIUM PHARMACEUTICALS INC is ATNM and it is listed on the NYSE Arca exchange.
On which exchange is ATNM stock listed?
ATNM stock is listed on the NYSE Arca exchange.
What is the price forecast or stock price prediction for ACTINIUM PHARMACEUTICALS INC stock?
11 analysts have analysed ATNM and the average price target is 5.1 USD. This implies a price increase of 249.32% is expected in the next year compared to the current price of 1.46. Check the ACTINIUM PHARMACEUTICALS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is ACTINIUM PHARMACEUTICALS INC worth?
ACTINIUM PHARMACEUTICALS INC (ATNM) has a market capitalization of 45.55M USD. This makes ATNM a Nano Cap stock.
How many employees does ACTINIUM PHARMACEUTICALS INC have?
ACTINIUM PHARMACEUTICALS INC (ATNM) currently has 37 employees.
What are the support and resistance levels for ACTINIUM PHARMACEUTICALS INC (ATNM) stock?
ACTINIUM PHARMACEUTICALS INC (ATNM) has a support level at 1.45 and a resistance level at 1.57. Check the full technical report for a detailed analysis of ATNM support and resistance levels.
Is ACTINIUM PHARMACEUTICALS INC (ATNM) expected to grow?
The Revenue of ACTINIUM PHARMACEUTICALS INC (ATNM) is expected to decline by -100% in the next year. Check the estimates tab for more information on the ATNM EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy ACTINIUM PHARMACEUTICALS INC (ATNM) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of ATNM, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of ATNM, evaluating the profitability, health, valuation and growth aspects
- ACTINIUM PHARMACEUTICALS INC (ATNM) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- ACTINIUM PHARMACEUTICALS INC (ATNM) Sales and EPS estimates to see what analysts future expectations are.
- ACTINIUM PHARMACEUTICALS INC (ATNM) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- ACTINIUM PHARMACEUTICALS INC (ATNM) Insider and Institutional Ownership to learn about the owners and their transactions.
- ACTINIUM PHARMACEUTICALS INC (ATNM) Stock Chart to make your own analysis
- ACTINIUM PHARMACEUTICALS INC (ATNM) Latest news and press-releases to stay up to date.
Does ACTINIUM PHARMACEUTICALS INC (ATNM) stock pay dividends?
ATNM does not pay a dividend.
When does ACTINIUM PHARMACEUTICALS INC (ATNM) report earnings?
ACTINIUM PHARMACEUTICALS INC (ATNM) will report earnings on 2025-11-12.
What is the Price/Earnings (PE) ratio of ACTINIUM PHARMACEUTICALS INC (ATNM)?
ACTINIUM PHARMACEUTICALS INC (ATNM) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.31).
What is the Short Interest ratio of ACTINIUM PHARMACEUTICALS INC (ATNM) stock?
The outstanding short interest for ACTINIUM PHARMACEUTICALS INC (ATNM) is 2.86% of its float. Check the ownership tab for more information on the ATNM short interest.
ATNM Technical Analysis
ATNM Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to ATNM. While ATNM seems to be doing ok healthwise, there are quite some concerns on its profitability.
ATNM Financial Highlights
Over the last trailing twelve months ATNM reported a non-GAAP Earnings per Share(EPS) of -1.31. The EPS increased by 13.82% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -65.12% | ||
| ROE | -215.83% | ||
| Debt/Equity | 0 |
ATNM Forecast & Estimates
11 analysts have analysed ATNM and the average price target is 5.1 USD. This implies a price increase of 249.32% is expected in the next year compared to the current price of 1.46.
For the next year, analysts expect an EPS growth of -7.22% and a revenue growth -100% for ATNM